Given the close pathophysiological link between MAFLD and type 2 diabetes (T2DM), drug development companies are actively exploring T2DM therapeutics such as thiazolidinediones, GLP1R glucagon-like peptide 1 receptor (GLP1R) agonists, farnesoid X receptor (FXR) agonists, and sodium–glucose cotransporter-2 (SGLT2) inhibitors for MAFLD treatment in ongoing human clinical trials [11]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.